AGM/EGMMay 29, 2026, 04:54 PM
Spyre Therapeutics Stockholders Approve ESPP, Elect Directors; Harwin Resigns
AI Summary
Spyre Therapeutics, Inc. held its Annual Meeting of Stockholders on May 27, 2026, where several key proposals were approved. Stockholders voted to approve the amended and restated 2016 Employee Stock Purchase Plan and elected three Class I directors: Mark McKenna, Cameron Turtle, and Laurie Stelzer. Additionally, Peter Harwin resigned from the Board, reducing its size to seven directors. Stockholders also approved the compensation of named executive officers on an advisory basis and ratified KPMG LLP as the independent registered public accounting firm.
Key Highlights
- Stockholders approved the amended and restated 2016 Employee Stock Purchase Plan.
- Mark McKenna, Cameron Turtle, and Laurie Stelzer were elected as Class I directors.
- Peter Harwin resigned from the Board, reducing its size from eight to seven directors.
- Executive officer compensation was approved on a non-binding, advisory basis.
- KPMG LLP was ratified as the independent auditor for the year ending December 31, 2026.
Price Impact
More from SYRE